Aveo

AVEO Oncology is passionate in our pursuit of improving the lives of patients with cancer.

Find out More
AVEO Oncology is passionate in our pursuit of improving the lives of patients with cancer.

Find out More
AVEO Oncology is passionate in our pursuit of improving the lives of patients with cancer.

Find out More
AVEO Oncology is passionate in our pursuit of improving the lives of patients with cancer.

Find out More

FOTIVDA™ (tivozanib) approved for treatment of RCC in Europe
DATA READOUT EXPECTED IN 4Q 2018

A Phase 3 Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC

Preliminary Phase 2 Results Presented at ASCO GU 2018

Latest Events

Leerink Partners Roundtable Series: Rare Disease & Oncology
Wednesday, October 3, 2018 at 1:00 p.m. Eastern Time

2018 Cantor Global Healthcare Conference
Tuesday, October 2, 2018 at 4:00 p.m. Eastern Time

B. Riley FBR Healthcare Conference
Tuesday, September 4, 2018 at 3:25 p.m. Eastern Time

Latest News

AVEO Oncology and EUSA Pharma Announce Updated Interim Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
October 22, 2018

AVEO Oncology to Present Updated Interim Results from the Phase 2 Portion of the TiNivo Study of Tivozanib and Nivolumab (OPDIVO®) in RCC at the ESMO 2018 Annual Congress
October 8, 2018

AVEO Oncology Announces Initiation of Topline Analysis of Phase 3 TIVO-3 Trial
October 1, 2018

© 2018 AVEO Pharmaceuticals, Inc. All rights reserved.

Contact Us | Site Map | Terms of Use | Privacy Policy